These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16097181)

  • 21. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug committees are necessary, according to the SNS reference group].
    Allebeck P
    Lakartidningen; 2005 Apr 4-10; 102(14):1070. PubMed ID: 15892479
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacy newsletters: time for a new approach.
    Mitchell JF
    Hosp Formul; 1985 Mar; 20(3):360, 363-5. PubMed ID: 10270308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of drug reports for the P&T Committee.
    Longe RL; Cross GW; Riley MW
    Hosp Formul; 1978 Mar; 13(3):228-9. PubMed ID: 10306915
    [No Abstract]   [Full Text] [Related]  

  • 26. Developing guidelines for biotechnology drug use: experience with antithrombin III.
    Romac DR; Poole P; Owings JT; Mahackian K; Foulke G; Tharratt RS; Albertson TE
    Formulary; 1995 Sep; 30(9):520-3, 525-7, 531. PubMed ID: 10151737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New thinking necessary?].
    Lindberg M
    Ugeskr Laeger; 2003 Oct; 165(41):3939-40. PubMed ID: 14579559
    [No Abstract]   [Full Text] [Related]  

  • 28. [The chairman of the drug committees: limit the reporting requirement between pharmacy and the prescribing physician concerning generic drug exchange].
    Back S; Widäng K
    Lakartidningen; 2002 Dec; 99(49):5005. PubMed ID: 12522991
    [No Abstract]   [Full Text] [Related]  

  • 29. [Reply 1: LAKSAK supports wise drug therapy using knowledge and sharp IT-tools].
    Gustafsson LL; Hensjö LO
    Lakartidningen; 2000 Sep; 97(39):4347. PubMed ID: 11076480
    [No Abstract]   [Full Text] [Related]  

  • 30. [The right drug to the right patient in a right dosage is the goal of clinical pharmacology].
    Lindell B
    Lakartidningen; 1984 May; 81(19):1931-43. PubMed ID: 6727471
    [No Abstract]   [Full Text] [Related]  

  • 31. The 'wise list'- a comprehensive model for drug and therapeutics committees to achieve adherence to recommendations for essential drugs among prescribers?
    Stichele RV
    Basic Clin Pharmacol Toxicol; 2011 Apr; 108(4):221-3. PubMed ID: 21414142
    [No Abstract]   [Full Text] [Related]  

  • 32. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic approach to writing P&T drug reports.
    Longe RL
    Hosp Formul; 1978 Feb; 13(2):128-9. PubMed ID: 10306341
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drug committees in Sweden].
    Barkman R
    Tidsskr Nor Laegeforen; 1970 Jan; 90(1):1-3. PubMed ID: 5448711
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacy committees and the prescription of drugs].
    Boréus LO
    Lakartidningen; 1969 Jun; 66():Suppl II:44+. PubMed ID: 5384122
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug information services in Nepal: the changing perspectives.
    Chhetri AK; Palaian S; Mishra P
    Kathmandu Univ Med J (KUMJ); 2008; 6(1):117-21. PubMed ID: 18604128
    [No Abstract]   [Full Text] [Related]  

  • 37. [Explanation on indications and cost-efficiency of Inspra].
    Ohlsson-Onerud A; Pettersson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2087; discussion 290-2. PubMed ID: 16097182
    [No Abstract]   [Full Text] [Related]  

  • 38. The DERP: is it an effective methodology?
    Heaton AH
    Health Aff (Millwood); 2006; 25(4):W276-8. PubMed ID: 16757488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The true cost and benefit of medication reduction.
    Aurigemma R
    Del Med J; 2009 Apr; 81(4):163-4. PubMed ID: 19552220
    [No Abstract]   [Full Text] [Related]  

  • 40. [Are the drug committees sold?].
    Bystedt T; Gustavsson R
    Lakartidningen; 1993 Oct; 90(41):3518, 3523. PubMed ID: 8231491
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.